Human medicines European public assessment report (EPAR): Edistride, dapagliflozin, Date of authorisation: 09/11/2015, Revision: 27, Status: Authorised
Human medicines European public assessment report (EPAR): Edistride, dapagliflozin, Date of authorisation: 09/11/2015, Revision: 27, Status: Authorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
Edistride is a medicine used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease.
In type 2 diabetes, Edistride is used in adults and children from 10 years of age whose condition is not controlled well enough. It is used with appropriate diet and exercise in patients who cannot take metformin (another diabetes medicine). It can also be used as ‘add-on’ treatment to other diabetes medicines.
In chronic heart failure (inability of the heart to pump enough blood around the body), Edistride is used in adults who have symptoms of the disease. Edistride is also used in adults with chronic kidney disease.
Edistride contains the active substance dapagliflozin.
Expand section
Collapse section
How is Edistride used?
Edistride is available as tablets and can only be obtained with a prescription.
For type 2 diabetes, chronic heart failure and chronic kidney disease, the recommended dose of Edistride is 10 mg once a day.
For type 2 diabetes, if Edistride is used with insulin or medicines that help the body produce insulin, the doses of these medicines may need to be reduced to prevent hypoglycaemia (low blood sugar levels).
For more information about using Edistride, see the package leaflet or contact your doctor or pharmacist.
How does Edistride work?
The active substance in Edistride, dapagliflozin, blocks the action of a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2). As blood is filtered by the kidneys, SGLT2 stops the kidneys passing glucose from the blood into the urine. Patients with diabetes have high levels of glucose in the blood. By blocking the action of SGLT2, dapagliflozin causes the kidney to pass more glucose into the urine, thereby reducing the levels of glucose in the blood.
Blocking the action of SGLT2 also supports heart function in patients with chronic heart failure and kidney function in patients with chronic kidney disease, regardless of having diabetes. Dapagliflozin’s actions increase the elimination of salt and water in the urine. This decreases the overall blood volume, reducing the effort needed for the heart to pump blood, thereby improving its function in patients with heart failure.
What benefits of Edistride have been shown in studies?
Type 2 diabetes
Edistride was found effective in several studies in patients with type 2 diabetes. The main measure of effectiveness was the level of glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
In two studies involving 840 adults with type 2 diabetes, Edistride, when used alone, decreased HbA1c levels by 0.66 percentage points more than placebo (a dummy treatment) after 24 weeks. In four other studies involving over 2,300 adults, adding Edistride to other diabetes medicines decreased HbA1c levels by 0.54–0.68 percentage points more than adding placebo after 24 weeks.
In a study involving 814 adults with type 2 diabetes, Edistride used in combination with metformin was at least as effective as a sulphonylurea (another type of diabetes medicines) used with metformin. Both combinations reduced HbA1c levels by 0.52 percentage points after 52 weeks.
A long-term study, involving over 17,000 adults with type 2 diabetes, looked at the effects of dapagliflozin on cardiovascular (heart and circulation) disease. The study indicated that dapagliflozin's effects were in line with those of other diabetes medicines that also work by blocking SGLT2.
The effects of Edistride in combination with metformin and/or insulin were also investigated in a study involving 72 children and young adults between 10 and 24 years of age with type 2 diabetes. Although HbA1c levels decreased in patients treated with Edistride compared with those given placebo, the results of the study alone were not robust enough to demonstrate the effect of Edistride in children. However, these results and additional data on the disease in children and data on how the medicine is absorbed, modified and removed from the body in children compared with adults support that Edistride works in the same way in children and in adults.
Heart failure
Edistride was effective at reducing the risk of death, hospitalisation or urgent medical visit due to heart failure in two main studies involving about 4,700 and 6,200 adult patients with heart failure. In these studies, Edistride was compared with placebo, both added to the patients’ usual treatment for heart failure.
The first study involved patients with heart failure with reduced ejection fraction (when the muscle of the heart is not pumping blood as well as normal). The rate of death and hospitalisation or urgent medical visit per 100 patient years was 11.6 in the Edistride group compared with 15.6 in the placebo group; the risk was 26% lower with Edistride than with placebo.
The second study involved patients with heart failure without reduced ejection fraction. The rate of death, hospitalisation or urgent medical visit per 100 patient years was 7.8 in the Edistride group compared with 9.6 in the placebo group; the risk was 18% lower with Edistride than with placebo.
Chronic kidney disease
Edistride was effective in treating adult patients with chronic kidney disease based on a study involving over 4,300 patients. When Edistride was added to patients’ usual treatment for chronic kidney disease, the proportion of patients that experienced a decline in kidney function, severe kidney disease or death was 9.2% among those taking Edistride, compared with 14.5% among those taking placebo; the risk was 39% lower with Edistride than with placebo.
What are the risks associated with Edistride?
The most common side effect with Edistride in patients with type 2 diabetes (which may affect more than 1 in 10 people) is hypoglycaemia (low blood sugar levels) when used in combination with a sulphonylurea or insulin.
For the full list of side effects and restrictions with Edistride, see the package leaflet.
Why is Edistride authorised in the EU?
The European Medicines Agency considered that Edistride was effective for treating type 2 diabetes in adults and children from 10 years of age when given alone or in combination with other diabetes medicines which work in different ways. In addition, beneficial reductions in weight and blood pressure occurred in patients treated with Edistride. In heart failure, Edistride can reduce the risk of death or serious complications in patients with heart failure. In patients with chronic kidney disease Edistride can reduce the risk of kidney function decline or death due to kidney or heart problems, when added to the patient’s usual treatment.
Edistride’s common side effects were related to raised levels of sugar in the urine, such as increased genital and, to a smaller degree, urinary infection, and are considered manageable.
The Agency concluded that the benefits of Edistride outweigh its risks and recommended that it be granted marketing authorisation.
What measures are being taken to ensure the safe and effective use of Edistride?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Edistride have been included in the summary of product characteristics and the package leaflet.
As for all medicines, data on the use of Edistride are continuously monitored. Side effects reported with Edistride are carefully evaluated and any necessary action taken to protect patients.
Other information about Edistride
Edistride received a marketing authorisation valid throughout the EU on 9 November 2015. This authorisation was based on the authorisation granted for Forxiga in 2012.
Edistride : EPAR - Medicine overview
Reference Number:
EMA/12587/2023
English (EN) (127.5 KB - PDF)
First published:
10/12/2015
Last updated:
06/03/2023
View
Edistride : EPAR - Risk management plan
English (EN) (671.85 KB - PDF)
First published:
10/12/2015
Last updated:
11/06/2026
View
Product information
Edistride : EPAR - Product information
English (EN) (996.16 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
Other languages (24)
български (BG) (945.37 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
español (ES) (967.3 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
čeština (CS) (863.36 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
dansk (DA) (703.46 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
Deutsch (DE) (999.97 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
eesti (ET) (747.09 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
ελληνικά (EL) (917.26 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
français (FR) (1.05 MB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
hrvatski (HR) (965.67 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
italiano (IT) (869.75 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
latviešu (LV) (1.07 MB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
lietuvių (LT) (1.16 MB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
magyar (HU) (1.05 MB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
Malti (MT) (1.02 MB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
Nederlands (NL) (967.36 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
polski (PL) (878.79 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
português (PT) (892.8 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
română (RO) (1.13 MB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
slovenčina (SK) (830.67 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
slovenščina (SL) (965.56 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
suomi (FI) (1.06 MB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
svenska (SV) (895.47 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
Íslenska (IS) (884.12 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
norsk (NO) (981.6 KB - PDF)
First published:
10/12/2015
Last updated:
13/03/2026
View
Latest procedure affecting product information:
VR/0000310736
12/03/2026
This medicine’s product information is available in all official EU languages. Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Edistride : EPAR - All Authorised presentations
English (EN) (27.12 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
Other languages (24)
български (BG) (31.32 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
español (ES) (26.09 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
čeština (CS) (27.66 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
dansk (DA) (27.18 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
Deutsch (DE) (27.84 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
eesti (ET) (26.41 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
ελληνικά (EL) (29.67 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
français (FR) (27.1 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
hrvatski (HR) (29.79 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
italiano (IT) (27.65 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
latviešu (LV) (27.48 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
lietuvių (LT) (27.97 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
magyar (HU) (27.49 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
Malti (MT) (28.73 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
Nederlands (NL) (26.12 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
polski (PL) (28.71 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
português (PT) (27.08 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
română (RO) (27.25 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
slovenčina (SK) (28.7 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
slovenščina (SL) (27 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
suomi (FI) (26.07 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
svenska (SV) (25.98 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
Íslenska (IS) (27.07 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
norsk (NO) (27.12 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
Product details
Name of medicine
Edistride
Active substance
dapagliflozin propanediol monohydrate
International non-proprietary name (INN) or common name
dapagliflozin
Therapeutic area (MeSH)
- Diabetes Mellitus, Type 2
- Heart Failure, Systolic
- Heart Failure
- Renal Insufficiency, Chronic
Anatomical therapeutic chemical (ATC) code
A10BK01
Pharmacotherapeutic group
Drugs used in diabetes
Therapeutic indication
Type 2 diabetes mellitus
Edistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.
For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.
Heart failure
Edistride is indicated in adults for the treatment of symptomatic chronic heart failure.
Chronic kidney disease
Edistride is indicated in adults for the treatment of chronic kidney disease.
Authorisation details
EMA product number
EMEA/H/C/004161
Marketing authorisation holder
AstraZeneca AB
151 85 Sodertalje Sweden
Opinion adopted
23/09/2015
Marketing authorisation issued
09/11/2015
Revision
27
Assessment history
Expand section
Collapse section
Changes since initial authorisation of medicine
Edistride : EPAR - Procedural steps taken and scientific information after authorisation
English (EN) (150.96 KB - PDF)
First published:
13/03/2026
View
Edistride : EPAR - Procedural steps taken and scientific information after authorisation (archive)
English (EN) (275.68 KB - PDF)
First published:
14/04/2016
Last updated:
13/03/2026
View
Edistride-H-C-PSUSA-00010029-202310 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
Reference Number:
EMA/504919/2024
English (EN) (129.16 KB - PDF)
First published:
31/10/2024
View
Edistride-H-C-PSUSA-00010029-202110 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)
Adopted
Reference Number:
EMA/700831/2022
English (EN) (151.49 KB - PDF)
First published:
01/03/2023
View
Edistride-H-C-WS-2299 : EPAR - Assessment report - Variation
Adopted
Reference Number:
EMA/954956/2022
English (EN) (2.27 MB - PDF)
First published:
01/03/2023
View
Edistride : EPAR - Paediatric investigation plan compliance statement
Reference Number:
EMA/CHMP/592350/2022
English (EN) (104.54 KB - PDF)
First published:
27/06/2022
View
Edistride-H-C-WS-1952 : EPAR - Assessment report - Variation
Adopted
Reference Number:
EMA/622203/2021
English (EN) (1.97 MB - PDF)
First published:
20/01/2022
View
CHMP post-authorisation summary of positive opinion for Edistride (WS-1952)
Adopted
Reference Number:
EMA/CHMP/589418/2021
English (EN) (145.69 KB - PDF)
First published:
15/10/2021
View
Edistride-H-C-WS-1941 : EPAR - Assessment report - Variation
Adopted
Reference Number:
EMA/431093/2021
English (EN) (5.42 MB - PDF)
First published:
02/09/2021
View
CHMP post-authorisation summary of positive opinion for Edistride (WS-1941)
Adopted
Reference Number:
EMA/CHMP/347889/2021
English (EN) (145.19 KB - PDF)
First published:
25/06/2021
View
Edistride-H-C-4161-WS-1737 : EPAR - Assessment report - Variation
Adopted
Reference Number:
EMA/574301/2020
English (EN) (6.72 MB - PDF)
First published:
25/11/2020
View
CHMP post-authorisation summary of positive opinion for Edistride (WS-1737)
Adopted
Reference Number:
EMA/CHMP/551424/2020
English (EN) (123.01 KB - PDF)
First published:
16/10/2020
View
Edistride-H-C-4161-WS-1539 : EPAR - Assessment report - variation
Adopted
Reference Number:
EMA/476671/2019
English (EN) (1.46 MB - PDF)
First published:
29/08/2019
View
CHMP post-authorisation summary of positive opinion for Edistride (WS1539/0029)
Adopted
Reference Number:
EMA/CHMP/365313/2019
English (EN) (74.88 KB - PDF)
First published:
28/06/2019
View
Edistride-H-C-4161-WS-1344 : EPAR - Assessment report - variation
Reference Number:
EMA/CHMP/213138/2019 Corr.11
English (EN) (5.61 MB - PDF)
First published:
08/04/2019
View
Edistride-H-C-PSUSA-00010029-201610 : EPAR - Scientific conclusion and grounds for the variation to the terms of the marketing authorisation
Adopted
Reference Number:
EMA/465597/2017
English (EN) (64.94 KB - PDF)
First published:
20/07/2017
Last updated:
20/07/2017
View
Edistride-H-A20-1442-C-4161-0010 : EPAR - Assessment Report - Article 20
Adopted
Reference Number:
EMA/PRAC/637349/2016
English (EN) (254.07 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
Edistride-H-A20-1442-C-4161-0010 : EPAR - Scientific Conclusion - Article 20
English (EN) (41.36 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
Other languages (24)
български (BG) (84.18 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
español (ES) (41.99 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
čeština (CS) (78.08 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
dansk (DA) (41.03 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
Deutsch (DE) (44.39 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
eesti (ET) (40.46 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
ελληνικά (EL) (84.71 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
français (FR) (42.93 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
hrvatski (HR) (76.27 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
italiano (IT) (40.72 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
latviešu (LV) (76.13 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
lietuvių (LT) (72.25 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
magyar (HU) (60.56 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
Malti (MT) (83.36 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
Nederlands (NL) (42.37 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
polski (PL) (62.96 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
português (PT) (42.06 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
română (RO) (78.32 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
slovenčina (SK) (70.79 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
slovenščina (SL) (75.63 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
suomi (FI) (40.53 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
svenska (SV) (41.68 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
Íslenska (IS) (40.74 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
norsk (NO) (40.5 KB - PDF)
First published:
05/07/2017
Last updated:
05/07/2017
View
Initial marketing authorisation documents
CHMP post-authorisation summary of opinion for Edistride (WS-2299)
Adopted
Reference Number:
EMA/CHMP/938371/2022
English (EN) (176.46 KB - PDF)
First published:
16/12/2022
View
Edistride : EPAR - Public assessment report
Adopted
Reference Number:
EMA/679678/2015
English (EN) (226.11 KB - PDF)
First published:
10/12/2015
Last updated:
10/12/2015
View
CHMP summary of positive opinion Edistride
Adopted
Reference Number:
EMA/CHMP/524152/2015
English (EN) (69.91 KB - PDF)
First published:
25/09/2015
Last updated:
25/09/2015
View
News on Edistride
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2022
16/12/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021
15/10/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021
25/06/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2020
16/10/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019
28/06/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019
01/02/2019
First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes
01/02/2019
SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis
12/02/2016
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 September 2015
25/09/2015
More information on Edistride
Topics
This page was last updated on
11/06/2026
Summary
Human medicines European public assessment report (EPAR): Edistride, dapagliflozin, Date of authorisation: 09/11/2015, Revision: 27, Status: Authorised